Eli Lilly and Company (LLY) Wednesday reported new long-term data for its atopic dermatitis treatment Ebglyss. The results were reported from ADjoin long-term extension study.
In the study, adults and adolescents with moderate-to-severe atopic dermatitis who responded to Ebglyss in ADvocate 1 and 2 studies at week 16 were continued on monthly maintenance treatment for up to 3 years. More than 80 percent of this population experienced sustained skin clearance.
The safety profile of these patients was consistent with previous Ebglyss studies, and no new safety signals were observed up to three years of treatment.
Ebglyss is approved in the U.S, EU, and Japan to treat moderate-to-severe atopic dermatitis.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.